Novel drug reduced tumors, bone pain in advanced prostate cancer
Cabo RDT P2 CRPC results published in HEMONC Today 2/13/13. The article itself is straight forward Cabo reporting based upon the Nov 2012 JCO release, but there are two interesting oncologist's perspectives in tail comments from Drs Jorge Garcia and Donald L Trump that are noteworthy.
The comments by Drs. Garcia and Trump seem very positive.
According to Dr Trump "Although these are important trials and will lead to FDA approval of cabozantinib more quickly than other designs, it is my prediction — based on results of many other studies in many other types of cancer — that the greatest impact of this new agent will be if activity can be established in patients earlier in the course of disease (eg, androgen deprivation plus cabozantinib, docetaxel plus cabozantinib, etc). "
According to Dr Garcia, "First, this is the first "non-hormonal" agent in CRPC with clinical activity. Second, the type of responses observed in some of the patients in the study are not commonly seen in routine clinical practice."
More comments from the article:
"Randomization stopped early due to the dramatic effects observed on bone scans.
“Discontinuing randomization is not common,” Smith saidin a press release. “Stabilization of disease in advanced prostate cancer is rarely due to the natural history of the disease and is in this case due to drug effect.”
Seventy-two percent of patients had a regression in soft tissue lesions. Sixty-eight percent of patients showed improvement on bone scan, including complete resolution in 12%, according to study results.
“The effects of cabozantinib on bone scans are unprecedented in the treatment of prostate cancer,” Smith said.
Nine patients (5%) reached a confirmed partial response at 12 weeks and 127 patients (75%) achieved stable disease.
Before the suspension of randomization, researchers randomly assigned 31 patients with castration-resistant prostate cancer to cabozantinib (n=14) or placebo (n=17).
Patients who remained on the study drug experienced significantly longer PFS than those who received placebo (23.9 weeks vs. 5.9 weeks; P
As these posted reiterations come in from the Nov JCO RDT P2 study, I've made it a point to find out whether the publishing entity supports an editiorial OPED type format. Occasionally it pays off with some measure of informed commentary ...